Poseida Therapeutics Inc (PSTX) Stock: Evaluating the Annual Growth

In the past week, PSTX stock has gone up by 1.37%, with a monthly gain of 3.00% and a quarterly surge of 261.28%. The volatility ratio for the week is 1.55%, and the volatility levels for the last 30 days are 1.10% for Poseida Therapeutics Inc The simple moving average for the past 20 days is 1.27% for PSTX’s stock, with a 153.68% simple moving average for the past 200 days.

Is It Worth Investing in Poseida Therapeutics Inc (NASDAQ: PSTX) Right Now?

PSTX has 36-month beta value of 1.63. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 5 as “hold,” and 0 as “sell.”

The public float for PSTX is 67.38M, and currently, short sellers hold a 5.32% ratio of that float. The average trading volume of PSTX on January 07, 2025 was 1.34M shares.

PSTX) stock’s latest price update

Poseida Therapeutics Inc (NASDAQ: PSTX)’s stock price has increased by 0.52 compared to its previous closing price of 9.56. However, the company has seen a 1.37% increase in its stock price over the last five trading sessions. businesswire.com reported 2024-12-20 that NEW YORK–(BUSINESS WIRE)–Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Poseida Therapeutics, Inc. (NASDAQ: PSTX) to Roche Holdings, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $4.00 per share in cash upon achievement of specific milestones, is fair to Poseida shareholders. Halper Sadeh encourages Poseida shareholders to click here to learn more about their le.

Analysts’ Opinion of PSTX

Many brokerage firms have already submitted their reports for PSTX stocks, with Piper Sandler repeating the rating for PSTX by listing it as a “Neutral.” The predicted price for PSTX in the upcoming period, according to Piper Sandler is $10 based on the research report published on December 02, 2024 of the previous year 2024.

H.C. Wainwright, on the other hand, stated in their research note that they expect to see PSTX reach a price target of $15. The rating they have provided for PSTX stocks is “Buy” according to the report published on January 04th, 2023.

Cantor Fitzgerald gave a rating of “Overweight” to PSTX, setting the target price at $24 in the report published on January 07th of the previous year.

PSTX Trading at 47.30% from the 50-Day Moving Average

After a stumble in the market that brought PSTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.41% of loss for the given period.

Volatility was left at 1.10%, however, over the last 30 days, the volatility rate increased by 1.55%, as shares surge +2.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +296.90% upper at present.

During the last 5 trading sessions, PSTX rose by +1.32%, which changed the moving average for the period of 200-days by +215.95% in comparison to the 20-day moving average, which settled at $9.49. In addition, Poseida Therapeutics Inc saw 0.10% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at PSTX starting from Gergen Mark J, who sale 30,000 shares at the price of $9.46 back on Dec 10 ’24. After this action, Gergen Mark J now owns 651,291 shares of Poseida Therapeutics Inc, valued at $283,866 using the latest closing price.

Gergen Mark J, the Executive Chairman of Poseida Therapeutics Inc, sale 30,000 shares at $9.27 during a trade that took place back on Nov 26 ’24, which means that Gergen Mark J is holding 651,291 shares at $278,100 based on the most recent closing price.

Stock Fundamentals for PSTX

Current profitability levels for the company are sitting at:

  • -0.41 for the present operating margin
  • 0.95 for the gross margin

The net margin for Poseida Therapeutics Inc stands at -0.39. The total capital return value is set at -0.29. Equity return is now at value -57.63, with -20.39 for asset returns.

Based on Poseida Therapeutics Inc (PSTX), the company’s capital structure generated 0.4 points at debt to capital in total, while cash flow to debt ratio is standing at -0.26. The debt to equity ratio resting at 0.68. The interest coverage ratio of the stock is -6.89.

Currently, EBITDA for the company is -109.04 million with net debt to EBITDA at -0.72. When we switch over and look at the enterprise to sales, we see a ratio of 6.44. The receivables turnover for the company is 10.23for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.20.

Conclusion

To put it simply, Poseida Therapeutics Inc (PSTX) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Most Popular

Related Posts